These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36119532)

  • 1. Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study.
    Zhang W; Zhang Z; Lou S; Li D; Ma Z; Xue L
    Front Oncol; 2022; 12():929342. PubMed ID: 36119532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study.
    Yang X; Yin X; Qu X; Guo G; Zeng Y; Liu W; Jagielski M; Liu Z; Zhou H
    J Gastrointest Oncol; 2023 Dec; 14(6):2425-2435. PubMed ID: 38196544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
    Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
    J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
    He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
    J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer.
    An TQ; Qiu H; Zhou QB; Zong H; Hu S; Lian YG; Zhao RH
    World J Gastrointest Oncol; 2024 Jun; 16(6):2449-2462. PubMed ID: 38994132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer.
    Li Q; Cheng X; Zhou C; Tang Y; Li F; Zhang B; Huang T; Wang J; Tu S
    Front Oncol; 2022; 12():841977. PubMed ID: 35371995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer.
    Sun L; Huang S; Li D; Mao Y; Wang Y; Wu J
    Front Oncol; 2021; 11():754881. PubMed ID: 34692541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 blockade combined with chemotherapy and bevacizumab in DNA mismatch repair-proficient/microsatellite stable colorectal liver metastases.
    Men Q; Duan Y; Pei F; Yao Q; He W; Zhao Y; Shi L; Liu G; Huang J
    J Gastrointest Oncol; 2024 Aug; 15(4):1534-1544. PubMed ID: 39279968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).
    Zhao W; Lei J; Ke S; Chen Y; Xiao J; Tang Z; Wang L; Ren Y; Alnaggar M; Qiu H; Shi W; Yin L; Chen Y
    EClinicalMedicine; 2023 Dec; 66():102315. PubMed ID: 38024475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
    Wang Y; Wei B; Gao J; Cai X; Xu L; Zhong H; Wang B; Sun Y; Guo W; Xu Q; Gu Y
    J Immunol; 2020 Nov; 205(10):2905-2915. PubMed ID: 33028620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis.
    Li J; Zhu JX; Zhang YX; Li SQ
    Oncol Lett; 2024 Apr; 27(4):153. PubMed ID: 38406596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study.
    Li J; Cong L; Liu J; Peng L; Wang J; Feng A; Yue J; Li L; Wang X; Wang X
    Front Oncol; 2020; 10():594125. PubMed ID: 33282742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study.
    Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY
    Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.
    Jiang FE; Zhang HJ; Yu CY; Liu AN
    Neoplasma; 2021 Jul; 68(4):861-866. PubMed ID: 33998237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China.
    Gou M; Qian N; Zhang Y; Yan H; Si H; Wang Z; Dai G
    Front Oncol; 2022; 12():851756. PubMed ID: 35875064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
    Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
    JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
    Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
    Front Oncol; 2022; 12():917353. PubMed ID: 36226061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
    Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
    JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors.
    Wang Y; Xu J; Dong M; Liu K; Lu Y; Chen K; Cao Y; Shi H; Bei Y; Li J; Zhao J; Cao Y; Lu N; Yang L; Liu H; Cai P; Li K; Yang T; He N; Dong J; Zhang C
    J Gastrointest Oncol; 2024 Aug; 15(4):1519-1533. PubMed ID: 39279967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.